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Abstract
Background: Stereotactic radiosurgery (SRS) has been increasingly applied for up to 10 brain metastases instead of
whole brain radiation therapy (WBRT) to achieve local tumor control while reducing neurotoxicity. Furthermore,
brain-metastasis incidence is rising due to the increasing survival of patients with cancer. Our aim was to analyze
the efficacy and safety of CyberKnife (CK) radiosurgery for elderly patients.
Methods: We retrospectively identified all patients with brain metastases ≥ 65 years old treated with CK-SRS at our
institution since 2011 and analyzed data of primary diseases, multimodality treatments, and local therapy effect
based on imaging follow-up and treatment safety. Kaplan–Meier analysis for local progression-free interval and
overall survival were performed.
Results: We identified 97 patients (233 lesions) fulfilling the criteria at the first CK-SRS. The mean age was 73.2 ± 5.8
(range: 65.0–87.0) years. Overall, 13.4% of the patients were > 80 years old. The three most frequent primary cancers
were lung (40.2%), kidney (22.7%), and malignant melanoma (15.5%). In 38.5% (47/122 treatments) multiple brain
metastases were treated with the CK-SRS, with up to eight lesions in one session. The median planning target
volume (PTV) was 1.05 (range: 0.01–19.80) cm3. A single fraction was applied in 92.3% of the lesions with a median
prescription dose of 19 (range: 12–21) Gy. The estimated overall survivals at 3-, 6-, and 12 months after SRS were 79,
55, and 23%, respectively. The estimated local tumor progression-free intervals at 6-, 12-, 24-, 36-, and 72 months
after SRS were 99.2, 89.0, 67.2, 64.6, and 64.6%, respectively. Older age and female sex were predictive factors of
local progression. The Karnofsky performance score remained stable in 97.9% of the patients; only one patient
developed a neurological deficit after SRS of a cerebellar lesion (ataxia, CTCAE Grade 2).
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Conclusions: SRS is a safe and efficient option for the treatment of elderly patients with brain metastases with
good local control rates without the side effects of WBRT. Older age and female sex seem to be predictive factors
of local progression. Prospective studies are warranted to clarify the role of SRS treatment for elderly patients.
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Background
Stereotactic radiosurgery (SRS), in place of whole brain
radiation therapy (WBRT), is the standard for patients
with 1–3 metastases and an effective treatment for pa-
tients with up to 10 lesions to reduce neurotoxicity and
preserve quality of life [1–5]. Brain metastases incidence
has been increasing and will continue to rise due to the
improvement of systemic therapies [1, 2, 6]. In the
current era of immunotherapy or other targeted therap-
ies, overall survival (OS) has increased; thus, the demand
for less toxic alternatives than WBRT and the need for
retreatment with radiosurgery for local progression or
for new cerebral lesions is on the rise [2, 7, 8]. It has
been postulated that in the near future, 70% of new can-
cer diagnoses per year will be reported among the eld-
erly [9, 10]. Consequently, clinicians are facing a larger
population of aging patients.
The management of the elderly remains an issue of de-
bate, as they comprise an inhomogeneous patient popu-
lation with diverse comorbidities and different levels of
fitness. Age and the Karnofsky performance score (KPS)
have been used to roughly categorize the patients, as
proposed by the recursive partitioning analysis (RPA) for
prognostic factors by the Radiation Therapy Oncology
Group, where patients ≥ 65 years old were classified as
patients at medium risk with RPA class II [11]. For pa-
tients ≥ 70 years who received GammaKnife SRS of their
brain metastases, Park et al. identified the graded prog-
nostic assessment (GPA) classification as a strong prog-
nostic factor for survival [12]. Nevertheless, elderly
patients are generally underrepresented in randomized
clinical trials, and thus clinical practice is based on small
patient series and personal experience and assessment of
the treating physician.
Importantly, SRS may represent the treatment of
choice considering the risk of cognitive decline in the
elderly after WBRT [13, 14]. However, few reports have
assessed the feasibility and efficacy of SRS in the elderly
using conventional linear accelerator (LINAC) or
GammaKnife-based SRS, and to our knowledge, none
have done so using a frameless technique with the
CyberKnife (CK, Accuray Inc., Sunnyvale, CA), an
image-guided robotic linear accelerator system [15–18].
Thus, our aim in this study was to characterize our eld-
erly patient cohort with brain metastases and to analyze
the efficacy and safety of CK-SRS in this population.
Methods
Study design
This retrospective analysis of patient data was approved
by the local ethics committee (EA1/233/18). We identi-
fied all patients with brain metastases who were ≥ 65
years old at the time of the first CK-SRS and who were
treated at our center between July 2011 and August
2018. We collected data on patient characteristics re-
garding the primary disease, treatment modalities, clin-
ical outcome, local and overall tumor control, and acute
and long-term treatment morbidity. The KPS score prior
and after the treatment was used to classify the clinical
status and course of the patients. New neurological defi-
cits were documented. To evaluate quality of life and
neurocognitive effects all answered EORTC QLQ-C30
and QLQ-BN20 questionnaires were additionally ana-
lyzed. The Common Terminology Criteria for Adverse
Events 5.0 (CTCAE) were used to report adverse effects
[19]. We also analyzed radiometric parameters such as
prescription dose, fractionation scheme and planning
target volume (PTV). The graded prognostic assessment
(GPA) score considering the age, KPS, the presence of
extracranial metastases, and the number of brain metas-
tases was calculated. For patients ≥ 65 years of age, a
score of 2.5–3.0 (Class 2) correlates with the best prog-
nosis, and a score of 0–1.0 points (Class 4) correlates
with the worst prognosis [20].
CyberKnife treatment
All patients included in the study were referred for CK-
SRS for a limited number of brain metastases. Resection
cavities were excluded from this analysis. The indication
for CK treatment was decided by a multidisciplinary
neuro-oncology board team including a radiation on-
cologist and a neurosurgeon. A thermoplastic mask was
individually produced for each patient for treatment
immobilization before contrast enhanced high-resolution
thin-slice (0.75 mm) computed tomography (CT). This
reference CT was co-registered to T1-weighted magnetic
resonance images (MRI: magnetization-prepared rapid
acquisition with gradient echo using gadolinium-based
contrast agents, 1.0 mm slice thickness) using MultiPlan
(Accuray Inc.).
The planning process with the prescription of dose,
fractionation scheme, target definition, and dose
optimization was executed by a team comprising a
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radiation oncologist, a neurosurgeon, and a radiation
physicist. The gross tumor volume (GTV) was defined
as the tumor volume based on contrast-enhanced CT
and MRI. PTV margins of 0–1 mm were chosen by the
physician under consideration of MRI quality and ac-
tuality, a size progression between MRI and planning
CT or if no contrast agent could be administered during
planning CT.
Different dose regimens were applied depending on
the closeness to organs at risk (OARs; such as the optic
nerves, chiasm, and brainstem), the size and previous
treatments. In general, SRS for brain metastases with a
diameter ≤ 2.0 cm is performed in single fraction and
> 2.0 cm in 3 fractions. If a brain metastasis is eloquently
located (e.g. in the brainstem or along the optic path-
way), either a reduction of the single fraction dose or
hypofractionation is performed, depending on how the
dose constraints are met. In case of a local recurrence
after a single dose SRS, the CyberKnife reirradiation is
preferably fractionated. For metastases ≤ 2 cm, the most
commonly administered dose was 20–21 Gy in single-
fraction SRS; for larger brain metastases, multisession
SRS with three fractions of 8–9 Gy and a total dose of
24 to 27 Gy was used. The doses were routinely pre-
scribed to the 70% isodose line covering the PTV. Dose
distributions were calculated with the Ray-tracing algo-
rithm. Dose constraints to OARs for single fraction CK-
SRS were as follows: ≤ 0.2 cm3 of the optic pathway
could receive 8.0 Gy with a maximum point dose of 10.0
Gy in ≤ 0.035 cm3, and ≤ 0.35/≤ 1.2 cm3 of the brainstem
(medulla) could receive 10.0/7.0 Gy with a maximum
point dose of 14.0 Gy in ≤ 0.035 cm3 [21]. The eyes were
generally not directly irradiated. The biological equiva-
lent dose for 2 Gy per fraction was calculated according
to the LQ-model assuming an α/β-ratio of 2 Gy for nor-
mal brain tissue (EQD22) and 10 Gy for tumoral tissue
(EQD210). The calculated EQD210 encompassing the
PTV was 50.0–54.3 Gy for a single fraction, 36.0–42.8 Gy
for three-fraction treatment and 31.3 Gy for five-fraction
treatment.
SRS was performed with a non-isocentric treatment
technique, tracking the patient’s skull approximately
every 60 s with x-rays for accurate beam delivery. One
session lasted between 30 and 120min. Patients rou-
tinely received a single dose of 4 mg dexamethasone
after the treatment to prevent adverse effects due to
post-radiosurgical tumoral or normal tissue swelling.
Follow-up
Every 3 months, a clinical evaluation and radiological
imaging using contrast-enhanced MRI were evaluated as
a follow-up assessment. The latest available follow-up
was included in this analysis. The KPS and new neuro-
logical deficits were separately documented prior to the
treatment and at the last follow-up. The MRI scans were
analyzed by the responsible physician to assess the re-
sponse to treatment. We first examined the local control
in the area of the PTV. The treatment response of each
lesion was assessed by the Response Assessment in
Neuro-Oncology Brain Metastases (RANO-BM) [22].
Local tumor control was achieved if the treated brain
metastases showed a complete response (disappearance
of the lesion), partial response (at least a 30% decrease
in the longest dimension), or stable disease without sig-
nificant change in size. Local progression of the disease
was assumed if a lesion increased by at least 20% in
diameter, and distant failure was defined as new metas-
tases diagnosed based on the follow-up MRI scans. OS
was calculated from the first CK-SRS until the analysis
for this study (07/19). The Berlin–Brandenburg tumor
registry was used to verify the surveillance.
Statistical analysis
Overall survival (OS) and progression-free survival were
investigated using Kaplan–Meier analysis. Progression-
free survivals for 6, 12, 24, 36, 48, and 60months were
calculated. Group comparisons were carried out using
log-rank tests. To assess the risk factors possibly associ-
ated with earlier local recurrence of brain metastases,
univariate and multivariate analyses were performed
using Cox regression analysis; parameters with p < 0.05
in the univariate analyses were entered into the multi-
variate analysis. The data are presented as median and
range. IBM SPSS Statistics (Version 25.0. Armonk, NY:




We analyzed the data of 233 treated lesions of 97 pa-
tients with brain metastases. Demographic and clinical
characteristics are summarized in Table 1. Overall,
54.6% of the patients were between 70 and 80 years old
and 13.4% were > 80 years; to attain a fair distribution of
the entire cohort, we categorized the patients in three
groups: < 70 (37.3%), 70 to 75 (32.2%), > 75 (30.5%) years
old. More than half of the patients were male (58.8%).
The three most frequent primary tumor types were lung
(40.2%), kidney (22.7%), and malignant melanoma
(15.5%; Table 1). A total of 14 patients had undergone
WBRT, 10 patients before and 3 patients after CK-SRS,
while in one case the time point was not documented
(Table 1). In the patient cohort, 29.9% (n = 29) of all pa-
tients had undergone a tumor resection prior to CK-SRS
for another lesion (Table 1). Additional systemic treat-
ment with chemotherapy and/or immunotherapy was
performed in 82.5% (n = 80) of the patients, while in
72.2% of the patients a chemo- or antihormonal
Acker et al. Radiation Oncology          (2020) 15:225 Page 3 of 10
therapy was documented. There was no relevant differ-
ence observed between the age groups (Table 2).
CK-SRS treatment characteristics
In 38.5% (47/122 treatments) of treatments, multiple
brain metastases were treated with CK-SRS, with up to
eight lesions in one session. In total, 14.4% of the pa-
tients (14 of 97) were treated repeatedly (up to four
times) with CK-SRS. The median PTV for the lesions
was 1.05 cm3 (range: 0.01 cm3–19.80 cm3). A single frac-
tion was used in 92.3% of the lesions with a median pre-
scription dose (PD) of 19 Gy (range: 12–21 Gy) and a
PTV of 0.93 cm3 (range: 0.01 cm3–11.10 cm3). The me-
dian PTV for the lesions that received hypofractioned
therapy in three fractions was 3.74 cm3 (range: 0.82
cm3–19.80 cm3) with a median PD of 27 Gy (range: 21–
27 Gy). The PTV for the only lesion treated by 25 Gy in
5 fractions was 13.9 cm3.
Overall survival and tumor control
The estimated OS rates at 3-, 6-, and 12-months after
SRS were 79, 55, and 23%, respectively. At least one
follow-up assessment with sufficient imaging material
was present in 77.3% of the patients and in 80.0% of the
lesions with a median follow-up period of 7.6 months
(range: 0.3–76.3 months). The estimated local tumor
progression-free interval fractions at 6-, 12-, 24-, 36-,
and 72months were 99.2, 89, 67.2, 64.6, and 64.6%, re-
spectively (Fig. 1). There were differences amongst the
different tumor origins (Fig. 2). Malignant melanoma
metastases achieved the best local control rates, although
without significant differences in comparison to the
other pathologies. The only significant difference was
detected between lung and breast cancer metastases,
with worse local control for breast tumors (Fig. 2; log
rank test, p = 0.034). A significant difference was seen
between patients < 70 and > 75 years old (Fig. 3a; log
rank test, p = 0.028). Furthermore, we compared local
progression between sexes, and found that local control
was worse for female patients (Fig. 3b; log rank test, p =
0.003). In this regard, we analyzed the proportion of
radioresistant tumors amongst both sexes. A total of
20.0% of female and 24.6% of the male patients had a
renal cell carcinoma, malignant melanoma was diag-
nosed in 12.5% of females and 19.3% of males. The radi-
ation therapy resistant histologies like malignant
melanoma and renal cell carcinoma were balanced be-
tween the sexes. Of the 9 female patients with breast
cancer, only one was diagnosed with triple negative.
Categorization of the local response could be per-
formed in 70.0% of the lesions with a minimum follow-
up period of 3 months (median: 10.3 months with a
range of 3.0–76.3 months; Table 3). Nearly half of the le-
sions (46.3%) achieved partial remission, whereas only






Age at diagnosis in years
Mean ± SD 70.1 ± 8.3
Age at 1. CK SRS in years
Mean ± SD 73.3 ± 5.8
Years from diagnosis to CK SRS
Mean ± SD 3.2 ± 5.0

















Cancer of unknown pathology 2.1%
Urothelial carcinoma 1.0%
Whole brain irradiation treatment (% of patients)
Without 83 (85.6%)
Prior to CK-SRS 10 (10.3%)





Extracranial metastases at diagnosis
Yes 72 (74.2%)
No 25 (25.8%)
CK CyberKnife, SRS Stereotactic radiosurgery, GPA Graded
prognostic assessment
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14.8% of the lesions showed local progression. Complete
remission was accomplished in 22.2% of the lesions. The
estimated distant tumor progression-free interval frac-
tions at 6-, 12-, 24-, 36-, and 72months were 80.0, 54.6,
36.2, 11.0, and 8.3%, respectively (Fig. 4).
Factors affecting local control
In the univariate cox proportional hazards regression
analyses, older age, female sex, and larger PTV were the
risk factors that reached significance (Table 4). In the
multivariate analysis, only older age and female sex
remained significant risk factors for local recurrence,
while PTV reached p = 0.051, remaining slightly above
the threshold of significance.
Morbidity, mortality and quality of life
No severe (>CTCAE Grade 2) acute complications oc-
curred. Overall, KPS remained stable in 97.9% of the pa-
tients, whilst only 1.0% deteriorated by ≥ 10 points
within the follow-up period. Patients > 75 years old also
tolerated the treatment well without major deterioration
(Fig. 5). Only one patient (1.0%) developed a new neuro-
logical deficit after SRS of a cerebellar lesion (ataxia,
CTCAE Grade 2). White matter changes such as edema
and/or necrosis as asymptomatic radiation-induced
imaging signs occurred in four patients (4.0%), while
intracranial hemorrhage developed in only one patient
with melanoma in four of five lesions without symptoms
due to minor bleeding. Overall, the rate of intracranial
hemorrhage for the patients with melanoma was
patient-based 6.6% (1 in 15 patients) and lesion-based
14.8% (4 in 27 lesions).
Of all 97 patients, two EORTC questionnaires (QLQ-
C30, QLQ-BN20) were available for 60–68 patients, at
first irradiation and 17–20 patients answered a follow-up
questionnaire, respectively. The median follow-up time
for the last latest questionnaire was 11months (range:
3–35 months). Mean scores of the subscales are listed in
Table 5. Physical and social functioning in EORTC
QLQ-C30 deteriorated after SRS, while drowsiness and
motor dysfunction were evaluated worse in EORTC
QLQ-BN20.
Discussion
Our study evaluated for the first time the efficacy and
safety of image-guided frameless CK-SRS in a large co-
hort of elderly patients. Our study supports the recom-
mendation of SRS for this population in light of the
reasonable local control rates with very rare
complications.









All patients 72.2 46.4 36.1 82.5
Age < 70 27.8 15.5 13.4 29.9
Age 70–75 26.8 13.4 11.3 28.9
Age > 75 17.5 17.5 11.3 23.7
Unknown 17.5 15.5 12.4 12.4
Fig. 1 The overall estimated local tumor progression-free interval.
Number of lesions at risk were 233 (0 months), 66 (12 months), 33
(24 months), 7 (36 months), 1 (60 months)
Fig. 2 The overall estimated local tumor progression-free interval
divided in the most frequent pathologies
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SRS provided advantages concerning the risk of neuro-
cognitive decline in an elderly population after radiation
therapy [13, 14]. Besides, the convenience of a short
treatment in an outpatient setting should be considered
as an advantage. However, the accumulated experience
with SRS for this specific patient population is based on
few reports using LINAC or GammaKnife-based SRS
[15–18]. As the OS after cancer diagnosis is on the rise
due to new therapeutic regimens, the role of radiosur-
gery will become more important for the treatment of
the elderly [2, 7–10].
In our series, the median follow-up time was 7.6
months with a wide range (0.3–76.3 months) due to the
different survival times of the patients. However, the
portion of the patients with a follow-up period more
than 2 years was low with 14.4%. The estimated local
control rates at 6-, 12-, 24-, 36-, and 72months were
99.2, 89.0, 67.2, 64.6, and 64.6%, respectively. Nearly half
of the lesions achieved partial remission, whereas only
14.8% showed local progression, defined as 20% tumor
growth. The most recent report using a LINAC-SRS
system analyzed 110 cerebral metastases in 40 patients
[18]. In that series, by Gregucci et al., the complete and
partial remission rates were comparable to those in our
series (complete remission: 10.9% vs. 22.2%; partial re-
mission: 46.4% vs. 46.3%), while the progressive disease
rate was lower in their series (1.0% vs. 14.8%) [17]. This
discrepancy is most probably due to the different defin-
ition of progression; they defined progression as 50%
tumor growth [18] compared to our series where it was
defined as 20%. Noel et al. reported on approximately
227 metastases in 117 elderly patients also using
LINAC-SRS with a local control rate of 91% at 12
Fig. 3 The overall estimated local tumor progression-free interval for different ages and sex. a, three groups divided by age < 70, 70 to 75, > 75
years. A significant difference was only seen between patients < 70 and > 75 years old (log rank test, p = 0.028). b, Furthermore, regarding the
overall estimated local tumor progression-free interval of male and female patients, female patients had worse local control compared to male
patients (log rank test, p = 0.003)
Table 3 Summary of different local response categories in a
total of 162 lesions with a minimum follow-up of 3 months
(median: 10.3 months with a range of 3.0–76.3 months)
Number of lesions %
Complete remission 36 22.2
Partial remission 75 46.3
Stable disease 27 16.7
Progressive disease 24 14.8
Fig. 4 The overall estimated distant tumor progression-free interval.
Number of lesions at risk were 233 (0 months), 54 (12 months), 25
(24 months), 5 (36 months), 0 (60 months)
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months, similar to our series [15]. Minniti et al. also re-
ported the results of a series of 102 elderly patients with
183 metastases treated with LINAC-SRS who attained
84% local control at 12 months (17). Kim et al. analyzed
74 metastases in 44 elderly patients treated with
GammaKnife, where local progression was observed in
12% of the patients [16]. Chen et al. compared 37 elderly
patients treated with CyberKnife or LINAC-SRS with 82
patients treated by WBRT focusing on toxicity [23]. The
authors concluded that WBRT was associated with
greater toxicity compared to SRS in elderly and very eld-
erly patients with brain metastases [23]. Gregucci et al.
also reported no severe adverse effects worse than grade
2 after SRS [18]. Mininiti et al. reported a neurological
complication rate of 13% [17]. In our series, KPS deteri-
orated by ≥ 10 points only in 1% of the patients, while
neurological complications occurred only in 1% of pa-
tients. Overall, 14 patients underwent WBRT, which
apparently did not cause more significant complications
than SRS alone. Evidence regarding the safety of SRS
after WBRT was recently reported by Lohkamp et al.
[24], and was confirmed by our study findings where
even fewer complications were observed.
Although, our study does not provide a head to head
comparison of SRS to WBRT, we have to highlight the
limitation of SRS in regard to the lack of distant control
with our estimated distant progression-free rates. The
prospective randomized trial by Brown et al. [5, 25] re-
ported a significantly shorter time to intracranial failure
for SRS alone compared with SRS plus WBRT (hazard
ratio, 3.6; 95% CI, 2.2–5.9; p < 0.001). Despite a better
intracranial tumor control rate associated with WBRT,
Table 4 Univariate and multivariate Cox regression analyses for factors affecting the time to local tumor control
Univariate Analyses Multivariate Analysis
HR 95% CI p-value HR 95% CI p-value
Age 1.136 1.048–1.231 0.002 1.135 1.028–1.258 0.012
Sex (male) 0.247 0.092–0.662 0.005 0.270 0.100–0.730 0.010
PTV 1.186 1.051–1.339 0.006 1.128 0.996–1.277 0.058
Prescribed dose* 0.732 0.498–1.074 0.111
Primary tumor 1.025 0.902–1.166 0.703
GPA class 1.266 0.633–2.530 0.505
HR Hazard ratio, CI Confidence interval, PTV Planning target volume, GPA Graded prognostic assessment. *for the prescribed dose only single fractions were
included. bold text: p ≤ 0.05 was regarded as significant
Fig. 5 A boxplot diagram for the Karnofsky Performance Score (KPS)
before and after treatment. Three groups divided by age (< 70, 70 to
75, > 75 years) showing an overall stable KPS after treatment. The
boxes represent the interquartile range, the thicker line inside the
boxes the median, and the whiskers indicate the range from
minimum to maximum, excluding outliers (circles)
Table 5 Average scores of the two EORTC quality of life scales
answered before the first stereotactic radiosurgery (SRS) and the
last available questionnaire per patient. *Subscales of EORTC
QLQ-C30: higher score is better. #For QLQ-BN20 subscales, a
higher score is worse. n = existing evaluable answers
Before SRS Latest follow-up
EORTC QLQ – C30* n = 63–68 n = 20
Global health status/Quality of life 48.4 46.0
Physical functioning** 63.3 55.8
Cognitive functioning 65.4 63.3
Role functioning 55.5 49.2
Emotional functioning 60.1 59.6
Social functioning** 58.5 45.0
EORTC QLQ – BN20# n = 60–62 n = 17
Visual disorder 30.1 49.0
Motor dysfunction** 48.1 60.8




Weakness of legs 35.2 37.3
** p < 0.05 (pairwise Wilcoxon signed-rank test for the comparison before and
after SRS)
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no improvement in survival time occurred. Importantly,
fewer patients underwent salvage therapy after SRS plus
WBRT than after SRS alone (7.8% vs 32.4%, respectively;
difference, − 24.6%; 95% CI, − 35.7 to − 13.5%; p < 0.001).
In our cohort, as a salvage treatment 21.6% (n = 21) of
the patients received another CK-SRS, 5.2% (n = 5) of
the patients needed a surgery and 3.1% (n = 3) required a
WBRT. These were well-tolerated. In regard of the qual-
ity of life, physical and social functioning as well as
drowsiness and motor dysfunction deteriorated in our
small cohort after SRS with complete questionnaires.
However, this subjective evaluation was not reflected in
the objective complications. Therefore, we assume that
older patients who continue to age during multimodal
treatment will experience some decrease in quality of
life. However, due to the low number of the question-
naires after the SRS our analysis cannot judge this aspect
sufficiently. In the series of Brown et al. [5, 25] there was
less cognitive deterioration at 3 months after SRS alone
(40/63 patients, 63.5%) than when combined with
WBRT (44/48 patients, 91.7%; difference, − 28.2%; 90%
CI, − 41.9 to − 14.4%; p < 0.001). Quality of life (QoL) was
higher at 3 months with SRS alone, including overall
quality of life (p = 0.001). A retrospective study by Chen
et al. [26] compared SRS and WBRT in 119 geriatric pa-
tients with overall 811 lesions (≥ 70 years, ≤ 10 brain
metastases). In univariate analysis, fatigue, headache and
RTOG CNS toxicity (68.0% vs. 89.0%, p = 0.009) and
KPS decline (2.0% vs. 35%. p = 0.0005) was significantly
lower in the SRS arm. The multivariate analysis con-
firmed a higher toxicity after 3 months for the WBRT
arm. In contrast to the QUARTZ study, where the com-
bination of WBRT and dexamethasone showed only a
small difference in QoL and no difference in OS between
the two groups [27], our data with a median survival of
55.6 weeks, preserved KPS and QoL, and no severe acute
complications, show a benefit of local therapy with the
CK-SRS instead of best supportive care. In light of this
accumulated evidence of good local control rates and
overall low toxicity rates, SRS should be preferred over
WBRT in elderly patients with a certain number of brain
metastases despite the limitation for distant tumor
control.
As SRS is a purely local therapy, we focused on pre-
dictive factors for local control rather than OS and dis-
tant progression-free control. The univariate analyses
identified older age, female sex, and larger PTV as risk
factors for local progression in our cohort, while in the
multivariate analysis older age and female sex remained
significant, with PTV approximating statistical signifi-
cance. Importantly, the primary diseases and GPA score
did not play a significant role in the regression analysis.
We chose the GPA score for our analysis because in two
previous studies the score index for radiosurgery (SIR)
was superior to the recursive partitioning analysis (RPA)
score and in a second analysis the GPA score was the
strongest prognostic factor for survival compared to the
SIRS [12, 28]. In regard to primary diseases, one possible
explanation could be more regular MRI brain scans in
some tumor entities such as melanoma in the routine
that enables a faster identification of a brain metastases
that then response better to a local treatment despite
radioresistancy. The prescribed dose did neither play a
role in the local control, that is probably due to the over-
all comparable dose regime in our cohort. Gregucci
et al. also identified PTV and BED ≥ 40 Gy as factors as-
sociated with local control [18], whereas Minniti et al.
could not identify factors predictive of local control [17].
The fact that female sex was identified as a risk factor in
our series might be due to the distribution of the pri-
mary tumors between the sexes. For instance, breast
cancer comprised up to 25% of the primary tumors
amongst women and had the worst local control. In this
regard, we analyzed the proportion of radioresistant tu-
mors amongst both sexes, however the radiation therapy
resistant histologies like malignant melanoma and renal
cell carcinoma were balanced between male and female.
Triple negative breast cancer was diagnosed in only one
woman. One further aspect is the total PTV pro patient
that was slightly higher for female patients but did not
reach a significant level. Overall, our data did not pro-
vide the reason for this observation between female and
male patients. We identified older age as a potential risk
factor for worse local control; however, Watabene et al.
performed a case-matched study comparing SRS applied
to very elderly (≥80 years old) patients with that applied
to patients between 65 and 79 years old [23] and re-
ported similar local control and complication rates be-
tween the groups, signifying that SRS should not be only
preserved for patients younger than 80 years [29]. We
assume that differences in systemic treatments provided
to very elderly patients may explain the effect of age on
local control. Although there was no obvious difference
in the analysis of the systemic therapy amongst different
age groups, we could not supply the exact treatment de-
tails. As this was a retrospective study, our data lacked
sufficient power to analyze this factor sufficiently.
The major weakness of this study was its retrospective
design and the unavoidable preselection of the patients
due to the outpatient treatment that requires a reason-
able pre-treatment KPS. In any case, our study provides
valuable data for this patient group, as it is the largest to
date published lesion series concerning elderly patients
with brain metastases who were treated using CK.
Conclusions
Radiosurgical treatment of elderly patients with brain
metastases could be a safe and efficient option with
Acker et al. Radiation Oncology          (2020) 15:225 Page 8 of 10
preserved KPS and QoL. The multivariate analysis shows
older age and female sex were predictive factors of local
progression, while for the GPA no significance was de-
tected. This analysis provides a basis for further SRS
treatment of elderly patients with a limited number of
metastases, despite the GPA classification.
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